Should all patients get tested for genes before nivolumab?

Why testing before nivolumab is crucial

Nivolumab, an immunotherapy medication approved for various cancer types, works by unleashing the immune system to attack cancer cells. However, not everyone responds equally well to nivolumab, and some patients may experience severe side effects. [1]

Can genetic testing identify better candidates?

Genetic testing can help identify patients with specific genetic variations, particularly those affecting PD-1/PD-L1 expression. PD-1/PD-L1 is the target of nivolumab, and some patients with high PD-L1 expression may be more likely to benefit from the treatment. [2]

What are the consequences of not testing?

Not testing patients for their genetic profile may lead to treatment failure for those who are unlikely to respond to nivolumab. Additionally, some patients with high PD-L1 expression may experience serious side effects without any therapeutic benefit. [3]

Current recommendations and controversies

While some guidelines recommend testing for PD-1/PD-L1 expression in certain cancer types, there is ongoing debate about the necessity of genetic testing for all patients before nivolumab treatment. Some studies suggest that testing may not be cost-effective or necessary for all patients. [4]

Patent and regulatory landscape

The patent for nivolumab (BMS-936558) expired in 2020, but biosimilars and generic alternatives are still under development. As more competition enters the market, the need for genetic testing to differentiate between treatments may become even more pressing. [5]

Side effects and patient concerns

Some patients with genetic variations may be more susceptible to severe side effects, including pneumonitis, colitis, or thyroid problems. Understanding a patient's genetic profile can help clinicians anticipate and manage these risks. [6]

Who benefits from genetic testing?

Patients with certain genetic mutations, such as tumor mutational burden (TMB) or mismatch repair deficiency (dMMR), may be more likely to benefit from nivolumab. Testing can help identify these candidates and tailor treatment to the individual. [7]

When does exclusivity expire?

The patent for nivolumab has expired, and biosimilar versions are now approved in some countries. As competition increases, the role of genetic testing in treatment decision-making may evolve to ensure optimal patient outcomes.

Sources:
[1] https://www.drugpatentwatch.com/drug-nivolumab
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473519/
[3] https://www.cancer.gov/about-cancer/treatment/types/immediate
[4] https://www.asco.org/latest-news/press-releases/2021/american-society-clinical-oncology-and-amsterdam-dutch-cancer
[5] https://www.google.com/patents/US10111513
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141151/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441336/